Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 2
2010 1
2011 1
2012 2
2013 2
2014 2
2015 3
2016 4
2018 3
2019 1
2020 1
2021 4
2022 1
2023 8
2024 2
2025 2
2026 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

38 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean P. toufi (7,045,876 results)?
Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease.
Bateman RJ, Smith J, Donohue MC, Delmar P, Abbas R, Salloway S, Wojtowicz J, Blennow K, Bittner T, Black SE, Klein G, Boada M, Grimmer T, Tamaoka A, Perry RJ, Turner RS, Watson D, Woodward M, Thanasopoulou A, Lane C, Baudler M, Fox NC, Cummings JL, Fontoura P, Doody RS; GRADUATE I and II Investigators and the Gantenerumab Study Group. Bateman RJ, et al. N Engl J Med. 2023 Nov 16;389(20):1862-1876. doi: 10.1056/NEJMoa2304430. N Engl J Med. 2023. PMID: 37966285 Free PMC article. Clinical Trial.
The change from baseline in the CDR-SB score at week 116 was 3.35 with gantenerumab and 3.65 with placebo in the GRADUATE I trial (difference, -0.31; 95% confidence interval [CI], -0.66 to 0.05; P = 0.10) and was 2.82 with gantenerumab and 3.01 with placebo in the GRADUATE …
The change from baseline in the CDR-SB score at week 116 was 3.35 with gantenerumab and 3.65 with placebo in the GRADUATE I trial (differenc …
Real-world observations of GLP-1 receptor agonists and SGLT-2 inhibitors as potential treatments for Alzheimer's disease.
Zhang P, Mao C, Sun A, Yang Y, Hou Y, Fu Z, Babak T, Leverenz JB, Pieper AA, Luo Y, Cummings J, Cheng F. Zhang P, et al. Alzheimers Dement. 2025 Sep;21(9):e70639. doi: 10.1002/alz.70639. Alzheimers Dement. 2025. PMID: 40898408 Free PMC article.

RESULTS: We identified GLP-1 receptor agonist initiation compared to DPP-4 inhibitors initiation was associated with a reduced risk of AD (hazard ratio [HR] 0.69 and P value < 0.001) and SGLT-2 inhibitor initiation compared to DPP-4 inhibitor initiation was associated

…
RESULTS: We identified GLP-1 receptor agonist initiation compared to DPP-4 inhibitors initiation was associated with a reduced risk of AD (h …
Relationships between plasma biomarkers, tau PET, FDG PET, and volumetric MRI in mild to moderate Alzheimer's disease patients.
Matthews DC, Kinney JW, Ritter A, Andrews RD, Toledano Strom EN, Lukic AS, Koenig LN, Revta C, Fillit HM, Zhong K, Tousi B, Leverenz JB, Feldman HH, Cummings J. Matthews DC, et al. Alzheimers Dement (N Y). 2024 Jul 9;10(3):e12490. doi: 10.1002/trc2.12490. eCollection 2024 Jul-Sep. Alzheimers Dement (N Y). 2024. PMID: 38988416 Free PMC article.
FDG PET and brain volumes correlate with tau PET in numerous regions (such as inferior temporal: p = 0.0007, p = 0.00001, respectively). NfL, GFAP, and all imaging modalities correlate with baseline MMSE; subsequent MMSE decline is predicted by baseline parahippocam …
FDG PET and brain volumes correlate with tau PET in numerous regions (such as inferior temporal: p = 0.0007, p = 0.00001, resp …
CSF α-Synuclein Seed Amplification Assays and Alzheimer Disease Biomarkers in Dementia With Lewy Bodies: Presentation and Progression.
Coughlin DG, Jain L, Khrestian M, Bozoki AC, Galvin JE, Irwin DJ, Lippa CF, Litvan I, Pillai JA, Tousi B, Lopez OL, Berman S, Tsuang DW, Zabetian CP, Fleisher JE, Taylor AS, Leverenz JB, Bekris LM, Galasko D; Dementia With Lewy Bodies Consortium. Coughlin DG, et al. Neurology. 2025 Dec 23;105(12):e214346. doi: 10.1212/WNL.0000000000214346. Epub 2025 Nov 17. Neurology. 2025. PMID: 41248454
AD+: Abeta42/40 abnormal, p-tau181, t-tau. Other non-AD: normal Abeta42/40 but elevated p-tau181 or t-tau levels). ...RESULTS: Ninety-nine participants had CSF alphaSyn-SAA and AD biomarkers available for analysis (mean age 69.8 6.6, 15% female); 68% (67/99) wer …
AD+: Abeta42/40 abnormal, p-tau181, t-tau. Other non-AD: normal Abeta42/40 but elevated p-tau181 or t-tau levels). ...RESULT …
ABO blood types and sepsis mortality.
Itenov TS, Sessler DI, Khanna AK, Ostrowski SR, Johansson PI, Erikstrup C, Pedersen OB, Rygård SL, Holst LB, Bestle MH, Hein L, Lindhardt A, Tousi H, Andersen MH, Mohr T, Lundgren JD, Jensen JU. Itenov TS, et al. Ann Intensive Care. 2021 Apr 20;11(1):61. doi: 10.1186/s13613-021-00844-2. Ann Intensive Care. 2021. PMID: 33877463 Free PMC article.
In a pooled analysis blood type B carried a slightly lower risk of 30-day all-cause mortality compared to non-blood type B (adjusted HR 0.88; 95%-CI 0.79-0.98; p = 0.02). There was no difference in the risk of AKI. Soluble thrombomodulin and syndecan-1 concentrations were …
In a pooled analysis blood type B carried a slightly lower risk of 30-day all-cause mortality compared to non-blood type B (adjusted HR 0.88 …
Antibiotic prescriptions among dentists across Norway and the impact of COVID-19 pandemic.
Tousi F, Al Haroni M, Lie SA, Lund B. Tousi F, et al. BMC Oral Health. 2023 Sep 8;23(1):649. doi: 10.1186/s12903-023-03380-6. BMC Oral Health. 2023. PMID: 37684614 Free PMC article.

An overall decrease in the number of prescriptions by health professions other than dentists during the 5 years (IRR = 0.92, 95% CI:0.92-0.93, p < 0.001) was observed. For dentists a slight increase in the number of prescriptions (IRR = 1.01, 95% CI: 1.01-1.01, p

…
An overall decrease in the number of prescriptions by health professions other than dentists during the 5 years (IRR = 0.92, 95% CI:0.92-0.9 …
SALL4 as a new biomarker for early colorectal cancers.
Ardalan Khales S, Abbaszadegan MR, Abdollahi A, Raeisossadati R, Tousi MF, Forghanifard MM. Ardalan Khales S, et al. J Cancer Res Clin Oncol. 2015 Feb;141(2):229-35. doi: 10.1007/s00432-014-1808-y. Epub 2014 Aug 26. J Cancer Res Clin Oncol. 2015. PMID: 25156818 Free PMC article.
RESULTS: The blood copy number of SALL4 in recruited CRC patients was significantly higher than healthy controls (p = 0.0001). This high copy number was not only inversely associated with the depth of tumor invasion (p = 0.045), but also was significantly correlated …
RESULTS: The blood copy number of SALL4 in recruited CRC patients was significantly higher than healthy controls (p = 0.0001). This h …
Sensorineural hearing loss in pseudoexfoliation syndrome.
Yazdani S, Tousi A, Pakravan M, Faghihi AR. Yazdani S, et al. Ophthalmology. 2008 Mar;115(3):425-9. doi: 10.1016/j.ophtha.2007.10.038. Epub 2008 Jan 9. Ophthalmology. 2008. PMID: 18187196
Mean ages of male and female participants did not significantly differ in cases versus controls (P = 0.88 and P = 0.83). Below average hearing thresholds were present in 88.4% of examined ears in the case group, versus 53.6% in the control group (P<0.001; …
Mean ages of male and female participants did not significantly differ in cases versus controls (P = 0.88 and P = 0.83). Below …
Phenotype and Genotype Correlation in Iranian Primary Congenital Glaucoma Patients.
Yazdani S, Miraftabi A, Pakravan M, Ghahari E, Tousi BK, Sedigh M, Yaseri M, Elahi E. Yazdani S, et al. J Glaucoma. 2016 Jan;25(1):33-8. doi: 10.1097/IJG.0000000000000206. J Glaucoma. 2016. PMID: 25580891
Patients with mutations also had significantly higher IOP throughout follow-up (P<0.002). The number of operations was significantly higher in subjects with mutations (3.3 1.8 vs. 1.8 1.5 procedures, P=0.025). Six patients (60%) with mutations were female as comp …
Patients with mutations also had significantly higher IOP throughout follow-up (P<0.002). The number of operations was significant …
Amygdala sign, a FDG-PET signature of dementia with Lewy Bodies.
Pillai JA, Wu G, Tousi B, Larvie M, Léger GC, Leverenz JB. Pillai JA, et al. Parkinsonism Relat Disord. 2019 Jul;64:300-303. doi: 10.1016/j.parkreldis.2019.03.005. Epub 2019 Mar 15. Parkinsonism Relat Disord. 2019. PMID: 30905401 Free PMC article.
RESULTS: Significant overlap between DLB and AD patients (occipital, parietal, temporal and frontal hypometabolism) and between DLB and FTD (frontal hypometabolism and the posterior cingulate sign) were identified. Right amygdala (p = 0.028) and right posterior cingulate ( …
RESULTS: Significant overlap between DLB and AD patients (occipital, parietal, temporal and frontal hypometabolism) and between DLB and FTD …
38 results